Teva Pharmaceutical Industries Ltd. (TEVA)
38.10
+1.17
(+3.17%)
USD |
NYSE |
Aug 25, 16:00
37.98
-0.12
(-0.31%)
Pre-Market: 05:58
Teva Pharmaceutical Industries Enterprise Value : 57.61B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 57.61B |
| August 24, 2026 | 56.25B |
| August 21, 2026 | 56.72B |
| August 20, 2026 | 56.11B |
| August 19, 2026 | 56.88B |
| August 18, 2026 | 55.84B |
| August 17, 2026 | 55.70B |
| August 14, 2026 | 56.06B |
| August 13, 2026 | 55.77B |
| August 12, 2026 | 56.03B |
| August 11, 2026 | 55.72B |
| August 10, 2026 | 55.33B |
| August 07, 2026 | 54.42B |
| August 06, 2026 | 53.78B |
| August 05, 2026 | 53.67B |
| August 04, 2026 | 53.33B |
| August 03, 2026 | 53.37B |
| July 31, 2026 | 54.01B |
| July 30, 2026 | 54.48B |
| July 29, 2026 | 53.66B |
| July 28, 2026 | 50.12B |
| July 27, 2026 | 49.43B |
| July 24, 2026 | 49.12B |
| July 23, 2026 | 49.55B |
| July 22, 2026 | 48.35B |
| Date | Value |
|---|---|
| July 21, 2026 | 49.75B |
| July 20, 2026 | 49.34B |
| July 17, 2026 | 50.54B |
| July 16, 2026 | 50.76B |
| July 15, 2026 | 49.99B |
| July 14, 2026 | 50.29B |
| July 13, 2026 | 50.71B |
| July 10, 2026 | 51.61B |
| July 09, 2026 | 51.78B |
| July 08, 2026 | 51.95B |
| July 07, 2026 | 53.59B |
| July 06, 2026 | 54.34B |
| July 02, 2026 | 53.58B |
| July 01, 2026 | 52.18B |
| June 30, 2026 | 52.69B |
| June 29, 2026 | 51.94B |
| June 26, 2026 | 51.83B |
| June 25, 2026 | 52.30B |
| June 24, 2026 | 53.00B |
| June 23, 2026 | 51.83B |
| June 22, 2026 | 50.65B |
| June 18, 2026 | 49.81B |
| June 17, 2026 | 51.07B |
| June 16, 2026 | 51.48B |
| June 15, 2026 | 52.39B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 686.06B |
| Eli Lilly & Co. | 1.207T |
| Bristol Myers Squibb Co. | 172.75B |
| RedHill Biopharma Ltd. | -- |
| MediWound Ltd. | 141.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -585.89M |
| Revenue (Quarterly) | 4.221B |
| Total Expenses (Quarterly) | 4.807B |
| EPS Diluted (Quarterly) | -0.5029 |
| Gross Profit Margin (Quarterly) | 52.07% |
| Profit Margin (Quarterly) | -13.88% |
| Earnings Yield | 1.56% |
| Operating Earnings Yield | 7.35% |
| Normalized Earnings Yield | 4.166 |